180 related articles for article (PubMed ID: 25190818)
1. Lamivudine/telbivudine-associated neuromyopathy: neurogenic damage, mitochondrial dysfunction and mitochondrial DNA depletion.
Xu H; Wang Z; Zheng L; Zhang W; Lv H; Jin S; Yuan Y
J Clin Pathol; 2014 Nov; 67(11):999-1005. PubMed ID: 25190818
[TBL] [Abstract][Full Text] [Related]
2. Telbivudine in liver transplant recipients: Renal protection does not overcome the risk of polyneuropathy and myopathy.
Turan I; Yapali S; Bademkiran F; Kose T; Duman S; Sozbilen M; Gunsar F; Ersoz G; Akarca US; Ozutemiz O; Karasu Z
Liver Transpl; 2015 Aug; 21(8):1066-75. PubMed ID: 25845464
[TBL] [Abstract][Full Text] [Related]
3. Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis.
Han Z; Shi Y; Zhu J; Chen Y; Yin F; Xia L; Luo G; Gao Z; Liu J; Jia G; Li C; Zhou X; Han Y
J Viral Hepat; 2013 Apr; 20 Suppl 1():58-64. PubMed ID: 23458526
[TBL] [Abstract][Full Text] [Related]
4. Myotoxicity of telbivudine in pre-existing muscle damage.
Finsterer J; Ay L
Virol J; 2010 Nov; 7():323. PubMed ID: 21083916
[TBL] [Abstract][Full Text] [Related]
5. Telbivudine myopathy in a patient with chronic hepatitis B.
Wang M; Da Y; Cai H; Lu Y; Wu L; Jia J
Int J Clin Pharm; 2012 Jun; 34(3):422-5. PubMed ID: 22527478
[TBL] [Abstract][Full Text] [Related]
6. Insights into the mechanisms of telbivudine-induced myopathy associated with mitochondrial dysfunction.
Yu W; Li Z; Wu W; Zhao D; Yan C; Lin P
Chem Biol Interact; 2023 Sep; 383():110692. PubMed ID: 37659625
[TBL] [Abstract][Full Text] [Related]
7. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment.
Fung J; Seto WK; Lai CL; Yuen MF
J Gastroenterol Hepatol; 2014 Mar; 29(3):428-34. PubMed ID: 24372662
[TBL] [Abstract][Full Text] [Related]
8. Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B.
Kim EH; Park H; Lee KH; Ahn SH; Kim SM; Han KH
Clin Mol Hepatol; 2013 Mar; 19(1):82-6. PubMed ID: 23593614
[TBL] [Abstract][Full Text] [Related]
9. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B.
Fleischer RD; Lok AS
J Hepatol; 2009 Oct; 51(4):787-91. PubMed ID: 19665816
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of telbivudine therapy in liver failure patients with chronic hepatitis B virus infection.
Wang L; Chen H; Fan C; Gong Z
J Med Virol; 2013 Nov; 85(11):1907-12. PubMed ID: 23852947
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir.
Park H; Park JY; Kim SU; Kim DY; Han KH; Chon CY; Ahn SH
World J Gastroenterol; 2013; 19(43):7671-9. PubMed ID: 24431895
[TBL] [Abstract][Full Text] [Related]
12. Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels.
Shi H; Han Z; Liu J; Xue J; Zhang S; Zhu Z; Xia J; Huang M
Med Sci Monit; 2017 Nov; 23():5230-5236. PubMed ID: 29095799
[TBL] [Abstract][Full Text] [Related]
13. DNMT1 modulation in chronic hepatitis B patients and hypothetic influence on mitochondrial DNA methylation status during long-term nucleo(t)side analogs therapy.
Madeddu G; Ortu S; Garrucciu G; Maida I; Melis M; Muredda AA; Mura MS; Babudieri S
J Med Virol; 2017 Jul; 89(7):1208-1214. PubMed ID: 27922198
[TBL] [Abstract][Full Text] [Related]
14. Toxic myopathy with multiple deletions in mitochondrial DNA associated with long-term use of oral anti-viral drugs for hepatitis B: A case study.
Fujii T; Takase KI; Honda H; Kawamura N; Yamasaki R; Urata M; Uchiumi T; Iwaki T; Kira JI
Neuropathology; 2019 Apr; 39(2):162-167. PubMed ID: 30847961
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological Features of Telbivudine-Associated Myopathy.
Ambang T; Tan JS; Ong S; Wong KT; Goh KJ
PLoS One; 2016; 11(9):e0162760. PubMed ID: 27611456
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine.
Safadi R; Xie Q; Chen Y; Yin YK; Wei L; Hwang SG; Zuckerman E; Jia JD; Lopez P
Liver Int; 2011 May; 31(5):667-75. PubMed ID: 21040410
[TBL] [Abstract][Full Text] [Related]
17. [The efficacy and safety of telbivudine in korean patients with chronic hepatitis B].
Moon YM; Hwang SG; Kim BS; Rim KS; Cho M; Kim DJ; Han JY; Kim YS; Choi HS; Ahn SH
Korean J Hepatol; 2007 Dec; 13(4):503-12. PubMed ID: 18159148
[TBL] [Abstract][Full Text] [Related]
18. Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis.
Yue-Meng W; Li YH; Wu HM; Yang J; Xu Y; Yang LH; Yang JH
Clin Exp Med; 2017 May; 17(2):233-241. PubMed ID: 27094312
[TBL] [Abstract][Full Text] [Related]
19. Decreased skeletal muscle mitochondrial DNA in patients with statin-induced myopathy.
Stringer HA; Sohi GK; Maguire JA; Côté HC
J Neurol Sci; 2013 Feb; 325(1-2):142-7. PubMed ID: 23312852
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D attenuates nucleoside reverse transcriptase inhibitor induced human skeletal muscle mitochondria DNA depletion.
Campbell GR; Pallack ZT; Spector SA
AIDS; 2013 Jun; 27(9):1397-401. PubMed ID: 23435299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
